Geptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancer
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This study is a multicenter, dose-escalating phase Ib clinical study to evaluate the safety
and tolerability of GB226 in combination with fruquintinib in the treatment of mCRC, evaluate
the pharmacokinetic characteristics of GB226 in combined therapy, evaluate immunogenicity of
GB226, and explore the antitumor activity of GB226 in combination with fruquintinib in the
treatment of mCRC.